Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies

Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies

Induction of broadly neutralising antibodies (bnAbs) capable of inhibiting infection with diverse variants of human immunodeficiency virus type 1 (HIV-1) is a key, as-yet-unachieved goal of prophylactic HIV-1 vaccine strategies. However some HIV-infected individuals develop bnAbs after ~2-4 years of...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Borrow, P, Moody, M
Μορφή:	Journal article
Έκδοση:	Wiley 2017

Παρόμοια τεκμήρια

Immune perturbations in HIV-1–infected individuals who make broadly neutralizing antibodies
ανά: Moody, M, κ.ά.
Έκδοση: (2016)

Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers
ανά: Elise Landais, κ.ά.
Έκδοση: (2018-09-01)

Immunologic Basis for Long HCDR3s in Broadly Neutralizing Antibodies against HIV-1
ανά: Lei eYu, κ.ά.
Έκδοση: (2014-06-01)

Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
ανά: Haynes, BF, κ.ά.
Έκδοση: (2022)

Broadly Neutralizing Antibody Responses in a Subset of HIV-1-Infected Individuals in Chennai, India
ανά: Syed Iqbal Hussain PhD, κ.ά.
Έκδοση: (2017-03-01)

Elimination of HIV-1-infected cells by broadly neutralizing antibodies
ανά: Timothée Bruel, κ.ά.
Έκδοση: (2016-03-01)

The expanding array of HIV broadly neutralizing antibodies
ανά: Laura E. McCoy
Έκδοση: (2018-10-01)

Broadly Neutralizing Antibodies for HIV-1 Prevention
ανά: Stephen R. Walsh, κ.ά.
Έκδοση: (2021-07-01)

The potential of broadly neutralizing antibodies for HIV prevention
ανά: Huub C. Gelderblom, κ.ά.
Έκδοση: (2024-05-01)

P04-26. Immunological tolerance prevents the expression of a broadly reactive neutralizing HIV-1 antibody
ανά: Kelsoe G, κ.ά.
Έκδοση: (2009-10-01)

Potent broadly neutralizing antibodies mediate efficient antibody-dependent phagocytosis of HIV-infected cells.
ανά: Brian J Snow, κ.ά.
Έκδοση: (2024-10-01)

A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.
ανά: Laura M Walker, κ.ά.
Έκδοση: (2010-08-01)

Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo
ανά: Lu, C.-L., κ.ά.
Έκδοση: (2017)

Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities
ανά: Yubin Liu, κ.ά.
Έκδοση: (2020-01-01)

Viral Vectors for the Induction of Broadly Neutralizing Antibodies against HIV
ανά: Sarah Wilmschen, κ.ά.
Έκδοση: (2019-09-01)

HIV-1 cell-to-cell transmission and broadly neutralizing antibodies
ανά: Jérémy Dufloo, κ.ά.
Έκδοση: (2018-07-01)

Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic
ανά: David A. Spencer, κ.ά.
Έκδοση: (2021-05-01)

Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies
ανά: Yousuf Ahmed, κ.ά.
Έκδοση: (2017-09-01)

Pharmacokinetics and immunogenicity of broadly neutralizing HIV monoclonal antibodies in macaques.
ανά: Yvonne Rosenberg, κ.ά.
Έκδοση: (2015-01-01)

Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies.
ανά: Laura E McCoy, κ.ά.
Έκδοση: (2015-08-01)

Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants
ανά: David R. Martinez, κ.ά.
Έκδοση: (2020-04-01)

Exploration of broadly neutralizing antibody fragments produced in bacteria for the control of HIV
ανά: Sarah B. Lloyd, κ.ά.
Έκδοση: (2017-11-01)

RAB11FIP5 expression and altered natural killer cell function are associated with induction of HIV broadly neutralizing antibody responses
ανά: Bradley, T, κ.ά.
Έκδοση: (2018)

P04-46. Broadly cross-neutralizing activity in plasma of HIV-1 and HIV-2 infected individuals
ανά: Aaby P, κ.ά.
Έκδοση: (2009-10-01)

Neutralizing the threat: harnessing broadly neutralizing antibodies against HIV-1 for treatment and prevention
ανά: Juan C Becerra, κ.ά.
Έκδοση: (2024-07-01)

Predicting neutralization susceptibility to combination HIV-1 monoclonal broadly neutralizing antibody regimens.
ανά: Brian D Williamson, κ.ά.
Έκδοση: (2024-01-01)

Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies.
ανά: Kong, R, κ.ά.
Έκδοση: (2012)

Immunological Fingerprints of Controllers Developing Neutralizing HIV-1 Antibodies
ανά: Martin-Gayo, Enrique, κ.ά.
Έκδοση: (2020)

The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV Antibodies
ανά: Sok, Devin, κ.ά.
Έκδοση: (2014)

Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells
ανά: Jérémy Dufloo, κ.ά.
Έκδοση: (2022-02-01)

Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection.
ανά: Kshitij Wagh, κ.ά.
Έκδοση: (2016-03-01)

Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort.
ανά: Landais, E, κ.ά.
Έκδοση: (2016)

Computational Prediction of Broadly Neutralizing HIV-1 Antibody Epitopes from Neutralization Activity Data
ανά: Ferguson, Andrew L., κ.ά.
Έκδοση: (2014)

Computational prediction of broadly neutralizing HIV-1 antibody epitopes from neutralization activity data.
ανά: Andrew L Ferguson, κ.ά.
Έκδοση: (2013-01-01)

PP 8.8 – 00129 Antibody mediated killing of HIV-1 infected cells with glycoengineered broadly neutralizing antibodies
ανά: S. De Taeye, κ.ά.
Έκδοση: (2022-12-01)

Engineering immunogens that select for specific mutations in HIV broadly neutralizing antibodies
ανά: Rory Henderson, κ.ά.
Έκδοση: (2024-11-01)

Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention.
ανά: Bryan T Mayer, κ.ά.
Έκδοση: (2022-04-01)

Immune System Regulation in the Induction of Broadly Neutralizing HIV-1 Antibodies
ανά: Garnett Kelsoe, κ.ά.
Έκδοση: (2013-12-01)

Conformational Plasticity in Broadly Neutralizing HIV-1 Antibodies Triggers Polyreactivity
ανά: Julie Prigent, κ.ά.
Έκδοση: (2018-05-01)

Characterization of V1V2-specific antibodies present in broadly neutralizing plasma isolated from HIV-1 infected individuals
ανά: Krachmarov C, κ.ά.
Έκδοση: (2012-09-01)